• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Blood Screening Market Share

    ID: MRFR/MED/5434-HCR
    85 Pages
    Rahul Gotadki
    September 2025

    Blood Screening Market Research Report By Technology (Nucleic Acid Amplification Test, Enzyme-Linked Immunosorbent Assay, Next-Generation Sequencing), Product and Services (Reagents, Instruments) and End User (Hospitals and Clinics) - Forecast till 2032

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Blood Screening Market Infographic

    Purchase Options

    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License

    Market Share

    Blood Screening Market Share Analysis

    The significance of being a critical component in healthcare has made it so competitive that firms always want higher shares among them. One common strategy used by most firms is differentiating their products from those offered by rivals. This might involve coming up with new technologies through which more accurate diagnostics can be done, like inventing one's biomarkers for use during such tests. Another strategy adopted by key players in this market is cost leadership. By focusing on operational efficiency and economies of scale, businesses can reduce their production costs and offer competitive prices for blood screening services. This has led to the rising popularity of their products among consumers, especially healthcare providers who are always on a budget, thereby increasing their market shares. The blood screening industry is affected by market positioning through strategic partnerships and collaborations. To widen their scope and reach out to new markets, companies may form unions with healthcare facilities, laboratories, or research groups. Another blood screening marketing share-increasing tactic involves expanding geographically. This will enable the corporation to target customers that were hitherto unreachable in such a manner. The expansion may require changing products and services to suit specific regional needs and regulatory requirements. In so doing, organizations make a stronger presence and increase the overall market share. Brand development, together with advertising, also plays an important role in defining a firm's market rate in the blood screening industry. Good brand building creates faithfulness among doctors as well as end users. To have a good image of the brand, firms must demonstrate that they have efficient blood screening services that are accurate when it comes to results obtained. To maintain or extend one's already acquired market share in the blood screening sector, customer-centric strategies are vital. With the aim of better suiting them, companies strive to understand the ever-changing requirements of health providers and labs that purchase their product range. Good customer service provision coupled with training courses related to those services and constant updates of the product based on clients' suggestions results in the satisfaction of these clients, thus ensuring retention.

    Market Summary

    The Global Blood Screening Market is projected to grow from 3.4 USD Billion in 2024 to 7.49 USD Billion by 2035.

    Key Market Trends & Highlights

    Blood Screening Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 7.45 percent from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 7.49 USD Billion, indicating robust growth potential.
    • In 2024, the market is valued at 3.4 USD Billion, reflecting a strong foundation for future expansion.
    • Growing adoption of advanced screening technologies due to increasing awareness of bloodborne diseases is a major market driver.

    Market Size & Forecast

    2024 Market Size 3.4 (USD Billion)
    2035 Market Size 7.49 (USD Billion)
    CAGR (2025-2035) 7.45%
    Largest Regional Market Share in 2024 latin_america)

    Major Players

    BioMerieux, Siemens Healthineers, Thermo Fisher Scientific Inc, Roche Diagnostics, Becton, Dickinson, and Company

    Market Trends

    Emergence of automated molecular platforms for blood screening to propel market growth

    Automated molecular platforms for blood screening are becoming a popular strategy among leading market players, fueling market growth. Blood screening tests aim to ensure the security of donated blood units and to find any signs of transmissible transfusion infections (TTIs) in the blood. The transition from manual to automated screening platforms has been critical in identifying contagious transfusion infections (TTIs) in blood samples. In the transfusion screening process, growing automation is anticipated to reduce human error. These screening tests generally impact most medical decisions in blood banks and hospitals.

    For instance, F. Hoffmann-La Roche Ltd. confirmed the CE-IVD launch of "cobas" in December 2019, which is intended to be utilized for blood donation screening and locates the Zika virus in human plasma. As a result, the adoption of these automated molecular platforms in blood donation facilities has increased due to the introduction of these platforms by key players. This will drive the growth of the blood screening market CAGR over the forecasted period.

    Other key factors boosting the development of the Blood Screening Market revenue include increasing blood donations and blood donors, raising awareness of the safety of donated blood, growing the prevalence of infectious diseases, and various government initiatives. The number of blood donations worldwide in 2022 is estimated to be around 118.5 million. Additionally, the WHO suggests that blood donations be screened for illnesses before use, including hepatitis B, syphilis, and other sexually transmitted diseases (STDs).

    The ongoing advancements in blood screening technologies, coupled with increasing regulatory emphasis on safety and quality, appear to be driving a transformative shift in the global landscape of blood diagnostics.

    U.S. Food and Drug Administration (FDA)

    Blood Screening Market Market Drivers

    Rising Prevalence of Bloodborne Diseases

    The increasing incidence of bloodborne diseases such as HIV, Hepatitis B, and Hepatitis C is a primary driver for the Global Blood Screening Market Industry. As awareness regarding these diseases grows, the demand for effective screening methods intensifies. For instance, the World Health Organization reports that millions are affected globally, necessitating robust screening protocols. This heightened focus on disease prevention is projected to contribute significantly to the market's growth, with the industry expected to reach 3.4 USD Billion in 2024 and potentially 7.49 USD Billion by 2035, reflecting a compound annual growth rate of 7.45% from 2025 to 2035.

    Market Segment Insights

    Blood Screening Technology Insights

    Based on materials, the Blood Screening Market segmentation includes nucleic acid amplification tests, enzyme-linked immunosorbent assay, and next-generation sequencing. The nucleic acid amplification tests segment held the majority share in 2022, contributing to around ~45-47% of the Blood Screening Market revenue. The advanced benefits of nucleic acid amplification test technology, such as high specificity and sensitivity for early detection, account for most of the share. The test detects nucleic acid sooner than other screening methods, narrowing the window period for HBV, HCV, and HIV infections.

    In addition, its largest share is also influenced by the technology's widespread use in hospitals, clinical labs, and blood banks. Moreover, the widespread adoption of this technology in developing and emerging markets creates new avenues for the segment's expansion.

    Figure 1: Global Blood Screening Market, by Technology, 2022 & 2032 (USD Billion)

    Source: Primary Research, Secondary Research, Market Research Future Database, and Analyst Review

    Blood Screening Product & Services Insights

    Applications have bifurcated the Blood Screening Market data into reagents and instruments. The reagents segment dominated the market in 2022 and is anticipated to be the faster-growing segment in the forecast period 2024-2032. Reagents, a recurring expense, are widely used in immunoassays and molecular tests. Factors such as increased blood donations and transfusion-related screenings, as well as the increasing prevalence of infectious diseases, are driving the growth of this segment. Additionally, the COVID-19 outbreak has increased serological testing, which has helped grow this market segment.

    These kits have uses in clinical chemistry, polymerase chain reaction (PCR), diabetes, in vitro and molecular diagnostics, test strips, and the detection of illicit drugs. Reagents and kits are also used privately or at the Point of Care (POC) for DNA lineage analysis, glucose strips, and at-home pregnancy tests.

    Blood Screening End User Insights

    Based on End Users, the global Blood Screening Market segmentation has been divided into hospitals, clinics, and others. Hospitals held the most prominent segment share in 2022 due to the increasing frequency of blood transfusion procedures in these settings. Many hospitals worldwide use patient blood management programs to help with transfusion, and screening practices, primarily to improve patient outcomes, cut costs and conserve blood units. Moreover, growing collaborations between blood centers and hospitals fuel the adoption of blood screening tests in these settings, driving the blood screening market growth throughout the forecast period.

    In December 2022, PredOmix introduced a novel blood test called OncoVeryx-F, which has a unique capability to accurately detect early-stage malignancies in women with a remarkable accuracy rate of 98%. Utilizing cutting-edge metabolomics technology in conjunction with artificial intelligence (AI), this novel advancement will facilitate the detection of early-stage malignancies through screening processes. The screening method, specifically tailored for the female population, effectively and precisely detects cancer at an early stage, prior to the initiation of tumor formation. The patented technology known as OncoVeryx-F integrates metabolomics and artificial intelligence methodologies for the purpose of early cancer detection.

    July 2023: Quest Diagnostics has recently introduced the inaugural direct-to-consumer blood test designed to identify atypical levels of beta amyloid, a crucial protein associated with Alzheimer's disease that may manifest years prior to the onset of dementia symptoms. The news is a result of the recent regulatory clearance in the United States of Leqembi, a pharmaceutical product developed by Eisai in collaboration with Biogen. Leqembi is designed to eliminate amyloid from the brain and has demonstrated efficacy in slowing the progression of Alzheimer's disease in individuals in the early stages of the condition.

    Get more detailed insights about Blood Screening Market Research Report - Forecast till 2032

    Regional Insights

    By Region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Blood Screening market accounted for USD 1.14 billion in 2022 and is likely to exhibit a significant CAGR growth over the study period. The region's largest share is mainly attributed to rising blood transfusion-related screenings, increasing infectious disease prevalence, an aging population, the need for early disease detection and monitoring, rising healthcare expenditure, and the growing adoption of technologically advanced blood screening technologies.

    This region's dominance is further attributed to increased blood donors, widespread implementation of blood screening procedures, and improved patient affordability.

    Further, the major countries studied in the global market report are the U.S., Germany, Canada, France, the UK, Spain, Italy, Japan, India, Australia, China, South Korea, and Brazil.

    Figure 3: BLOOD SCREENING MARKET SHARE BY REGION 2022 (%)BLOOD SCREENING MARKET SHARE BY REGION 2022

    Source: Primary Research, Secondary Research, Market Research Future Database, and Analyst Review

    The second-largest market share belongs to the European blood screening market, where respiratory illnesses and cancer are becoming more common. Rising government support and increased private-sector investment in the research and development of various blood screening tests are driving revenue growth in this region. For instance, F. Hoffmann-La Roche Ltd. introduced the Cobas Zika test for Cobas 6800/8800 Systems on December 16, 2019. The Cobas Zika test is designed to screen blood donations in Europe for Zika virus infection by finding RNA in human plasma samples.

    In addition, the European Union has made blood screening for HCV, HBV, HIV, parvovirus-19, and other viruses mandatory. Further, the German blood screening market held the largest market share, and the UK blood screening market was the fastest-growing market in the European region.

    The Asia-Pacific Blood Screening Market is projected to grow at the fastest CAGR from 2024 to 2032, owing to rising patient affordability and key industry players' increased focus on emerging markets. Japan, India, China, Singapore, and Australia contribute significantly to the market in the Asia Pacific region. Moreover, China’s blood screening market held the largest market share, and the Indian blood screening market was the fastest-growing market in the Asia-Pacific region.

    India's blood screening market differs from other Asia Pacific nations like China and Japan as of laxer regulatory requirements and the importation of the necessary equipment and materials. Expanded investments by private and international entities, which may help offer practical tests at lower prices, are expected to lead to significant growth in the Indian blood screening industry. India's well-connected network of clinical laboratories and healthcare facilities is accelerating the adoption of blood screening methods.

    Key Players and Competitive Insights

    The competitive landscape is semi-consolidated, with several domestic and international blood screening industry players operating globally. Major market players are investing heavily in research and development to develop more innovative and advanced techniques that minimize turnaround time and improve the effectiveness and accuracy of crossmatch screening. Key players use various market development strategies, including investing in adapting cutting-edge techniques, launching new technologies, mergers & acquisitions, and regional expansion to capture the largest share of global revenue.

    Blood screening industry competitors must provide cost-effective products and services to develop and sustain in an intensely challenging and rising global market environment. The blood screening market major players, such as BioMerieux, Siemens Healthineers, Thermo Fisher Scientific Inc, and others, are working to increase industry demand by investing in research and development activities to ensure constant innovation. The global blood screening industry has recently provided some of the most substantial advantages to reagents and instruments.

    Roche Diagnostics (Switzerland) is a company that provides diagnostic system solutions for hospitals, clinics, laboratories, and doctors' offices. The company creates, manufactures, and supports in-vitro diagnostic and bioanalytical instruments and software systems. It also provides test systems, molecular diagnostic reagents, blood screening products, diagnostic analysis systems, and workflow solutions. Blood glucose meters and point-of-care testing equipment are among its primary offerings. The company offers services and products to commercial diagnostic laboratories, hospitals, researchers, healthcare professionals, and pharmacists. Roche Diagnostics (Switzerland) purchased TIB Molbiol Group (Germany) in September 2021.

    This acquisition will broaden Roche's portfolio of molecular diagnostics solutions, including assays for infectious diseases, such as identifying SARS-CoV-2 variants.

    Also, Becton, Dickinson, and Company, or BD, is a multinational clinical technology company based in the United States that produces and distributes medical devices, indicator systems, and reagents. Additionally, in certain regions, BD offers consulting and analytics services. In March 2020, B.D. announced the launch of a singular blood screening test that can identify antibodies in blood to confirm current or previous COVID-19 exposure in less than 15 minutes.

    Key Companies in the Blood Screening Market market include

    Industry Developments

    June 2021: Grail, an American pharmaceutical and biotechnology company, has announced the release of the Galleri blood screening test, an advanced multi-cancer screening diagnostic that can detect the presence of multiple cancers. This test will assist the company in screening approximately 50 million people after its launch to obtain full FDA approval by 2023.

    May 2021: Tzar Labs, a molecular diagnostics company, and Epigeneres Biotechnology have announced the development of cancer tests for early detection. This test, which will be available by the end of 2023, will assist in determining the various stages of the disease. The company's accuracy rates for cancer screening tests are very high, and it has demonstrated results for all forms of cancer.

    October 2020: Siemens Healthineers has announced the availability of its laboratory-based total immunoglobulin test1 for identifying SARS-CoV-2 IgM and IgG immunoglobulin in the blood throughout the world. The ability to identify patients who have an adaptive immune response is made possible by the complete antibody test.

    Future Outlook

    Blood Screening Market Future Outlook

    The Global Blood Screening Market is projected to grow at a 7.45% CAGR from 2024 to 2035, driven by technological advancements, increasing disease prevalence, and rising awareness.

    New opportunities lie in:

    • Developing point-of-care testing solutions to enhance accessibility and speed.
    • Investing in AI-driven data analytics for improved screening accuracy.
    • Expanding partnerships with healthcare providers to broaden market reach.

    By 2035, the market is expected to exhibit robust growth, reflecting advancements and heightened demand.

    Market Segmentation

    Blood Screening End User Outlook

    • Hospitals
    • Clinics
    • Others

    Blood Screening Regional Outlook

    • US
    • Canada
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • Middle East
    • Africa
    • Latin America

    Blood Screening Technology Outlook

    • Nucleic Acid Amplification Test
    • Enzyme-Linked Immunosorbent Assay
    • Next-Generation Sequencing

    Blood Screening Product & Services Outlook

    • Reagents
    • Instrument

    Report Scope

    Report Attribute/Metric Details
    Market Size 2023 USD 2.70 billion
    Market Size 2024 USD 3.40 billion
    Market Size 2032 USD 5.60 billion
    Compound Annual Growth Rate (CAGR) 10.20% (2024-2032)
    Base Year 2023
    Market Forecast Period 2024-2032
    Historical Data 2019-2022
    Market Forecast Units Value (USD Billion)
    Report Coverage Market Competitive Landscape, Revenue Forecast, Growth Factors, and Trends
    Segments Covered Technology, Product & Services, End User, and Region
    Geographies Covered Europe, Asia Pacific, North America, and the Rest of the World
    Countries Covered The U.S., Germany, Canada, the UK, France, Italy, Spain, Japan, India, Australia, China, South Korea, and Brazil
    Key Companies Profiled BioMerieux, Bio-Rad Laboratories Inc, Siemens Healthineers, Ortho Clinical Diagnostics Inc, and Thermo Fisher Scientific Inc
    Key Market Opportunities ·         Technology improvements in blood screening equipment ·         Increase in the number of point-of-care (POC) testing facilities
    Key Market Dynamics ·         Increasing prevalence of infectious and chronic diseases worldwide ·         Increased demands for CBC tests during the COVID-19 pandemic

    Market Highlights

    Author

    Rahul Gotadki
    Assistant Manager

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    [email protected]

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    [email protected]

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM
    View All

    FAQs

    How much is the blood screening market?

    The Blood Screening Market size was valued at USD 2.70 Billion in 2023.

    What is the growth rate of the blood screening market?

    The global market is anticipated to grow at a CAGR of 10.20% over the projected period, 2024-2032.

    Which region held the largest market revenue share in the blood screening market?

    North America had the largest revenue share of the global market.

    Who are the key players in the blood screening market?

    The key players in the global market are BioMerieux, Bio-Rad Laboratories Inc, Siemens Healthineers, Ortho Clinical Diagnostics Inc, and Thermo Fisher Scientific Inc.

    Which technology led the blood screening market?

    The nucleic acid amplification test category dominated the market in 2023.

    Which end-user had the largest market share in the blood screening market?

    Hospitals had the most significant global market share.

    1. 'Table of Contents:    
    2. Chapter 1.    Report
    3. Prologue    
    4. Chapter 2.    Market Introduction  
    5.  
      1.     Definition    
      2.   
    6.  Scope of the Study    
      1.     Research
    7. Objective    
      1.     Assumptions  
        1.     Limitations    
    8. Chapter
    9.     Research Methodology
      1.     Introduction
      2.     Primary Research    
      3.   
    10.  Secondary Research    
      1.     Market Size
    11. Estimation
    12. Chapter 4.    Market Dynamics
      1.   
    13.  Drivers    
      1.     Restraints
      2.   
    14.  Opportunities    
      1.     Challenges
      2.     Macroeconomic Indicators
      3.     Technology
    15. Trends & Assessment
    16. Chapter 5.    Market Factor Analysis
      1.     Porter’s Five Forces Analysis
        1.   
    17.  Bargaining Power of Suppliers    
      1.     Bargaining
    18. Power of Buyers
      1.     Threat of New Entrants  
        1.     Threat of Substitutes    
        2.     Intensity of Rivalry    
      2.   
    19.  Value Chain Analysis
      1.     Investment Feasibility Analysis  
      2.     Pricing Analysis
    20. Chapter 6.    Global
    21. Blood Screening Market, by Technology
      1.     Introduction
      2.     Nucleic Acid Amplification Test (NAT)
        1. Transcription-Mediated
    22. Amplification (TMA)
    23. Market Estimates & Forecast, by Region, 2023-2030
    24. Market Estimates & Forecast, by Country, 2023-2030
    25.  6.2.2 Real-Time
    26. Polymerase Chain Reaction (PCR)
    27. Market Estimates & Forecast, by Region,
    28. 2030
      1.   
    29.  Enzyme-Linked Immunosorbent Assay (ELISA)
      1. ELISA Market, By Platform
    30. Market Estimates &
    31. Forecast, by Country, 2023-2030
      1. ELISA Market, By Generation
    32. Market
    33. Estimates & Forecast, by Region, 2023-2030
    34. Market Estimates & Forecast,
    35. by Country, 2023-2030
      1.     Rapid Tests
    36. Market Estimates
    37. & Forecast, by Region, 2023-2030
    38.            Market
    39. Estimates & Forecast, by Country, 2023-2030
      1.     Next-Generation
    40. Sequencing (NGS)
    41.          Market Estimates & Forecast, by Country, 2023-2030
      1.     Western Blotting
    42. Market Estimates & Forecast, by
    43. Region, 2023-2030
    44.            Market Estimates
    45. & Forecast, by Country, 2023-2030
    46. Chapter 7.    Global Blood
    47. Screening Market, by Product and Services
      1.     Introduction
      2.        Reagent and kits
        1. NAT Reagents &
    48. Kits
      1. ELISA Reagents & Kits
      2.     Enzymes and Polymerases
    49.        
    50.    Market Estimates & Forecast, by Country, 2023-2030
      1.   
    51.  Standards and Controls
    52.            Market Estimates & Forecast, by Country,
      1.     Probes and Primers
    53. Forecast, by Region, 2023-2030
      1.     Buffers,
    54. Nucleotides, and Solutions
      1.     Immunosorbents
      2.     Controls
    55.      
    56.      Market Estimates & Forecast, by Country, 2023-2030
      1.   
    57.  Instruments
      1. Rental Purchase
    58. by Region, 2023-2030
      1. Outright Purchase
      2.     Software
    59. and services
    60. Chapter 8.    Global
    61. Blood Screening Market, By End User
      1.        Hospitals
    62.        Clinics
    63.            Market Estimates & Forecast,
      1.         Research Institutes and
    64. Academic Center
      1.        Blood Banks
      2.        Others
    65.     Global Blood Screening Market, by Region
      1.   
    66.  Introduction
      1.     Americas
        1.     North
    67. America
      1.     US
        1.     Canada
        2.     South America
      2.     Europe
        1.   
    68.  Western Europe
      1.     Germany
        1.   
    69.  France
      1.     Italy
        1.     Spain
        2.     Eastern Europe
      2.     Asia-Pacific
        1.     Japan
        2.     China
        3.   
    70.  India
      1.     Australia
        1.     South
    71. Korea
      1.     Rest of Asia-Pacific
      2.     Middle
    72. East & Africa
      1.     Middle East
        1.   
    73.   Africa
    74. Chapter 10.    Company Landscape    
      1.     Introduction    
      2.     Market
    75. Share Analysis    
      1.     Key Development &
    76. Strategies    
    77. Chapter 11.    Company Profiles  
      1.     Grifols
        1.     Company
    78. Overview    
      1.     Product and Services Overview  
        1.     Financials Overview
        2.   
    79.  Key Developments    
      1.     SWOT Analysis  
      2.     F. Hoffmann-La Roche
        1.   
    80.  Company Overview    
      1.     Product
    81. and Services Overview    
      1.     Financial
        1.     Key Developments  
        2.     SWOT Analysis    
      2.   
    82.  Abbott Laboratories
      1.     Company Overview  
        1.     Product and Services Overview    
        2.     Financial Overview
        3.     Key
    83. Development    
      1.     SWOT Analysis  
      2.     Biomérieux
        1.     Company
        2.     Product and Services Overview  
        3.     Financial Overview    
        4.   
    84.  Key Development    
      1.     SWOT Analysis  
      2.     Bio-Rad Laboratories, Inc.
        1.   
        2.     Product
        3.     Financial
        4.     Key Developments
        5.   
    85.  SWOT Analysis        
      1.   
    86.  Siemens Healthineers (A Subsidiary of Siemens AG)
      1.   
        1.     Product
        2.     Financial
        3.     Key Developments
        4.   
      2.   
    87.  Ortho Clinical Diagnostics, Inc.
      1.     Overview  
        1.     Product and Services Overview    
        2.     Financial Overview    
        3.   
        4.     SWOT Analysis  
      2.     Thermo Fisher Scientific, Inc.
        1.   
    88.  Overview    
      1.     Product and Services
        1.     Financials  
        2.     Key Developments    
        3.   
    89.  SWOT Analysis
      1.     Beckman Coulter (A Subsidiary of
    90. Danaher Corporation)
      1.     Overview    
        1.     Product and Services Overview    
        2.   
    91.  Financials    
      1.     Key Developments  
        1.     SWOT Analysis
      2.   Becton, Dickinson
    92. and Company
      1.     Overview    
        1.   
    93.  Product and Services Overview    
      1.   
        1.     Key Developments  
        2.     SWOT Analysis
    94. Chapter 12  
    95.  MRFR Conclusion    
      1.     Key Findings  
        1.     From CEO’s Viewpoint    
        2.     Unmet Needs of the Market    
      2.   
    96.  Key Companies to Watch    
      1.     Predictions
    97. for the Blood Screening Market Industry
    98. Chapter 13.    Appendix
    99. LIST OF TABLES:
    100. Table 1       Global Blood Screening
    101. Market Synopsis, 2023-2030
    102. Table 2       Global Blood
    103. Screening Market Estimates and Forecast, 2023-2030 (USD Million)
    104. Table 3  
    105.     Global Blood Screening Market, by Region, 2023-2030 (USD Million)
    106. Table 4       Global Blood Screening Market, by Technology,
    107. 2030 (USD Million)
    108. Table 5       Global Blood Screening,
    109. by Product and Services, 2023-2030 (USD Million)
    110. Table 6      
    111. Global Blood Screening Market, by End User, 2023-2030 (USD Million)
    112. Table 7 
    113.      North America: Blood Screening Market, by Technology, 2023-2030
    114. (USD                    Million)
    115. Table 8       North America: Blood Screening, by Product and Services,
    116. Table 9       North America: Blood Screening
    117. Market, by End User, 2023-2030 (USD Million)
    118. Table 10     US: Blood
    119. Screening Market, by Technology, 2023-2030 (USD Million)
    120. Table 11   
    121.  US: Blood Screening Market, by Product and Services, 2023-2030 (USD Million)
    122. Table 12     US: Blood Screening Market, by End User, 2023-2030 (USD
    123. Million)
    124. Table 13     Canada: Blood Screening Market, by Technology,
    125. Table 14     Canada: Blood Screening Market,
    126. Table 15     Canada:
    127. Blood Screening Market, by End User, 2023-2030 (USD Million)
    128. Table 16  
    129.   South America: Blood Screening Market, by Technology, 2023-2030 (USD Million)
    130. Table 17     South America: Blood Screening Market, by Product and Services,
    131. Table 18     South America: Blood Screening
    132. Table 19     Europe:
    133. Blood Screening Market, by Technology, 2023-2030 (USD Million)
    134. Table 20  
    135.   Europe: Blood Screening Market, by Product and Services, 2023-2030 (USD Million)
    136. Table 21     Europe: Blood Screening Market, by End User, 2023-2030
    137. (USD Million)
    138. Table 22     Western Europe: Blood Screening Market,
    139. by Technology, 2023-2030 (USD Million)
    140. Table 23     Western Europe:
    141. Blood Screening Market, by Product and Services, 2023-2030 (USD Million)
    142. Table
    143.     Western Europe: Blood Screening Market, by End User, 2023-2030(USD
    144. Table 25     Eastern Europe: Blood Screening Market, by
    145. Technology, 2023-2030 (USD Million)
    146. Table 26     Eastern Europe:
    147.     Eastern Europe: Blood Screening Market, by End User, 2023-2030
    148. Table 28     Asia-Pacific: Blood Screening Market,
    149. Table 29     Asia-Pacific:
    150.     Asia-Pacific: Blood Screening Market, by End User, 2023-2030 (USD
    151. Table 31    Middle East & Africa: Blood Screening by
    152. Market, by Technology, 2023-2030 (USD Million)
    153. Table 32    Middle
    154. East & Africa: Blood Screening Market, by Product and Services, 2023-2030 (USD
    155. Table 33    Middle East & Africa Blood Screening Market,
    156. by End User, 2023-2030 (USD Million)
    157. LIST OF FIGURES:
    158. Figure 1  
    159.  Research Process
    160. Figure 2    Market Structure for Global
    161. Blood Screening Market
    162. Figure 3    Market Dynamics for Global
    163. Blood Screening Market 
    164. Figure 4    Global Blood Screening
    165. Market Share, by Technology, 2023
    166. Figure 5    Global Blood Screening
    167. Market Share, by Product and Services, 2023
    168. Figure 6    Global
    169. Blood Screening Market Share, by End User, 2023
    170. Figure 7    Global
    171. Blood Screening Market Share, by Region, 2023
    172. Figure 8    North
    173. America: Blood Screening Market Share, by Country, 2023
    174. Figure 9   
    175. Europe: Blood Screening Market Share, by Country, 2023
    176. Figure 10   Asia-Pacific:
    177. Blood Screening Market Share, by Country, 2023
    178. Figure 11   Middle
    179. East & Africa: Blood Screening Market Share, by Country, 2023
    180. Figure 12 
    181.  Global Blood Screening Market: Company Share Analysis, 2023 (%)
    182. Figure
    183. 13   Grifols: Key Financials
    184. Figure 14   Grifols: Segmental
    185. Revenue
    186. Figure 15   Grifols: Geographical Revenue
    187. Figure 16   F.
    188. Hoffmann-La Roche: Key Financials
    189. Figure 17   F. Hoffmann-La
    190. Roche: Segmental Revenue
    191. Figure 18   F. Hoffmann-La Roche: Geographical
    192. Figure 19   Abbott Laboratories: Key Financials
    193. 20   Abbott Laboratories: Segmental Revenue
    194. Figure 21   Abbott
    195. Laboratories: Geographical Revenue
    196. Figure 22   Biomérieux:
    197. Key Financials
    198. Figure 23   Biomérieux: Segmental Revenue
    199. Figure 24   Biomérieux: Geographical Revenue
    200. 25   Bio-Rad Laboratories, Inc.: Key Financials
    201. Figure 26   Bio-Rad
    202. Laboratories, Inc.: Segmental Revenue
    203. Figure 27   Bio-Rad Laboratories,
    204. Inc.: Geographical Revenue
    205. Figure 28   Siemens Healthineers
    206. (A Subsidiary of Siemens AG): Key Financials
    207. Figure 29   Siemens
    208. Healthineers (A Subsidiary of Siemens AG): Segmental Revenue
    209. Figure 30   Siemens
    210. Healthineers (A Subsidiary of Siemens AG): Geographical Revenue
    211. Figure 31   Ortho
    212. Clinical Diagnostics, Inc.: Key Financials
    213. Figure 32   Ortho
    214. Clinical Diagnostics, Inc.: Segmental Revenue
    215. Figure 33   Ortho
    216. Clinical Diagnostics, Inc.: Geographical Revenue
    217. Figure 34   Thermo
    218. Fisher Scientific, Inc.: Key Financials
    219. Figure 35   Thermo Fisher
    220. Scientific, Inc.: Segmental Revenue
    221. Figure 36   Thermo Fisher
    222. Scientific, Inc.: Geographical Revenue
    223. Figure 37   Beckman Coulter
    224. (A Subsidiary of Danaher Corporation): Key Financials
    225. Figure 38   Beckman
    226. Coulter (A Subsidiary of Danaher Corporation): Segmental Revenue
    227. Figure 39  
    228. Beckman Coulter (A Subsidiary of Danaher Corporation): Geographical Revenue 
    229. Figure 40   Becton, Dickinson and Company: Key Financials
    230. 41   Becton, Dickinson and Company: Segmental Revenue
    231. 42   Becton, Dickinson and Company: Geographical Revenue'

    Blood Screening Market Segmentation

    Blood Screening Technology Outlook (USD Billion, 2019-2030)

    • Nucleic Acid Amplification Test
    • Enzyme-Linked Immunosorbent Assay
    • Next-Generation Sequencing

    Blood Screening End User Outlook (USD Billion, 2019-2030)

    • Hospitals
    • Clinics
    • Others

    Blood Screening Product & Services Outlook (USD Billion, 2019-2030)

    • Reagents
    • Instrument

    Blood Screening Regional Outlook (USD Billion, 2019-2030)

    • North America Outlook (USD Billion, 2019-2030)

      • North America Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • North America Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • North America Blood Screening by Product & Services
        • Reagents
        • Instrument

      • US Outlook (USD Billion, 2019-2030)

      • US Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • US Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • US Blood Screening by Product & Services
        • Reagents
        • Instrument

      • CANADA Outlook (USD Billion, 2019-2030)

      • CANADA Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • CANADA Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • CANADA Blood Screening by Product & Services
        • Reagents
        • Instrument

    • Europe Outlook (USD Billion, 2019-2030)

      • Europe Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • Europe Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • Europe Blood Screening by Product & Services
        • Reagents
        • Instrument

      • Germany Outlook (USD Billion, 2019-2030)

      • Germany Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • Germany Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • Germany Blood Screening by Product & Services
        • Reagents
        • Instrument

      • France Outlook (USD Billion, 2019-2030)

      • France Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • France Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • France Blood Screening by Product & Services
        • Reagents
        • Instrument

      • UK Outlook (USD Billion, 2019-2030)

      • UK Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • UK Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • UK Blood Screening by Product & Services
        • Reagents
        • Instrument

      • ITALY Outlook (USD Billion, 2019-2030)

      • ITALY Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • ITALY Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • ITALY Blood Screening by Product & Services
        • Reagents
        • Instrument

      • SPAIN Outlook (USD Billion, 2019-2030)

      • Spain Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • Spain Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • Spain Blood Screening by Product & Services
        • Reagents
        • Instrument

      • Rest Of Europe Outlook (USD Billion, 2019-2030)

      • Rest Of Europe Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • REST OF EUROPE Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • REST OF EUROPE Blood Screening by Product & Services
        • Reagents
        • Instrument

    • Asia-Pacific Outlook (USD Billion, 2019-2030)

      • Asia-Pacific Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • Asia-Pacific Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • Asia-Pacific Blood Screening by Product & Services
        • Reagents
        • Instrument

      • China Outlook (USD Billion, 2019-2030)

      • China Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • China Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • China Blood Screening by Product & Services
        • Reagents
        • Instrument

      • Japan Outlook (USD Billion, 2019-2030)

      • Japan Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • Japan Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • Japan Blood Screening by Product & Services
        • Reagents
        • Instrument

      • India Outlook (USD Billion, 2019-2030)

      • India Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • India Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • India Blood Screening by Product & Services
        • Reagents
        • Instrument

      • Australia Outlook (USD Billion, 2019-2030)

      • Australia Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • Australia Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • Australia Blood Screening by Product & Services
        • Reagents
        • Instrument

      • Rest of Asia-Pacific Outlook (USD Billion, 2019-2030)

      • Rest of Asia-Pacific Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • Rest of Asia-Pacific Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • Rest of Asia-Pacific Blood Screening by Product & Services
        • Reagents
        • Instrument

    • Rest of the World Outlook (USD Billion, 2019-2030)

      • Rest of the World Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • Rest of the World Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • Rest of the World Blood Screening by Product & Services
        • Reagents
        • Instrument

      • Middle East Outlook (USD Billion, 2019-2030)

      • Middle East Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • Middle East Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • Middle East Blood Screening by Product & Services
        • Reagents
        • Instrument

      • Africa Outlook (USD Billion, 2019-2030)

      • Africa Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • Africa Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • Africa Blood Screening by Product & Services
        • Reagents
        • Instrument

      • Latin America Outlook (USD Billion, 2019-2030)

      • Latin America Blood Screening by Technology
        • Nucleic Acid Amplification Test
        • Enzyme-Linked Immunosorbent Assay
        • Next-Generation Sequencing
      • Latin America Blood Screening by End User
        • Hospitals
        • Clinics
        • Others
      • Latin America Blood Screening by Product & Services
        • Reagents
        • Instrument

     

    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Related Reports

    Regional Reports
    Country Reports

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials
    Global Magnesium Sulfate Market – Forecast till 2027